{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:35:29Z","timestamp":1790721329069,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["U19 AI113170"],"award-info":[{"award-number":["U19 AI113170"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2018.02.081","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T13:17:07Z","timestamp":1524057427000},"page":"7419-7426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Biological feasibility and importance of a gonorrhea vaccine for global public health"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-1813","authenticated-orcid":false,"given":"Leah R.","family":"Vincent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.081_b0005","series-title":"Sexually transmitted diseases","first-page":"451","article-title":"Gonococcal infections in the adult","author":"Hook","year":"1999"},{"key":"10.1016\/j.vaccine.2018.02.081_b0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/0956462416630909","article-title":"High prevalence of extra-genital chlamydial or gonococcal infections among high-risk men who have sex with men and transgender women in Lima, Peru","volume":"28","author":"Allan-Blitz","year":"2017","journal-title":"Int J STD & AIDS"},{"key":"10.1016\/j.vaccine.2018.02.081_b0015","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciu184","article-title":"Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men\u2013STD Surveillance Network, United States, 2010\u20132012","volume":"58","author":"Patton","year":"2014","journal-title":"Clin Infect Diseases: An Offic Publicat Infect Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2018.02.081_b0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra1411426","article-title":"Pelvic inflammatory disease","volume":"372","author":"Brunham","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2018.02.081_b0025","series-title":"Sexually transmitted diseases","first-page":"1089","article-title":"Sexually transmitted diseases, including HIV infection in pregnancy","author":"Watts","year":"1999"},{"key":"10.1016\/j.vaccine.2018.02.081_b0030","first-page":"1","article-title":"Ophthalmia neonatorum","volume":"2","author":"Palafox","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-74-6-979","article-title":"Disseminated gonococcal infection","volume":"74","author":"Holmes","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"24","key":"10.1016\/j.vaccine.2018.02.081_b0045","first-page":"85","article-title":"European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"2013","author":"Bignell","year":"2012","journal-title":"Int J STD & AIDS"},{"key":"10.1016\/j.vaccine.2018.02.081_b0050","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2018.02.081_b0055","unstructured":"Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and reports: MMWR 2015;64:1\u2013137."},{"key":"10.1016\/j.vaccine.2018.02.081_b0060","doi-asserted-by":"crossref","unstructured":"Dillon JA, Trecker MA, Thakur SD, Gonococcal Antimicrobial Surveillance Program Network in Latin A, Caribbean. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect. 2013;89 Suppl 4:iv36\u201341.","DOI":"10.1136\/sextrans-2012-050905"},{"key":"10.1016\/j.vaccine.2018.02.081_b0065","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.7205\/MILMED-D-13-00137","article-title":"Expanded sexually transmitted infection surveillance efforts in the United States military: a time for action","volume":"178","author":"Sanchez","year":"2013","journal-title":"Military Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0070","doi-asserted-by":"crossref","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0075","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1128\/AAC.01568-16","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae isolates (2010 to 2014) in France characterized by using whole-genome sequencing","volume":"60","author":"de Curraize","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.02.081_b0080","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3201\/eid2206.152091","article-title":"Neisseria gonorrhoeae resistant to ceftriaxone and cefixime, Argentina","volume":"22","author":"Gianecini","year":"2016","journal-title":"Emerg infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0085","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.02.081_b0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12941-016-0166-9","article-title":"Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary","volume":"15","author":"Brunner","year":"2016","journal-title":"Ann Clin Micro Antimicrob"},{"key":"10.1016\/j.vaccine.2018.02.081_b0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/sextrans-2015-052312","article-title":"An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England","volume":"92","author":"Chisholm","year":"2016","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.02.081_b0100","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0105","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/cid\/cix485","article-title":"Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016","volume":"65","author":"Katz","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0110","doi-asserted-by":"crossref","unstructured":"GBD 2016 DALYs and HALE collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1260\u2013344.","DOI":"10.1016\/S0140-6736(17)32130-X"},{"key":"10.1016\/j.vaccine.2018.02.081_b0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0968-8080(12)40653-X","article-title":"The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity","volume":"20","author":"Ndowa","year":"2012","journal-title":"Reprod Health Matters"},{"key":"10.1016\/j.vaccine.2018.02.081_b0120","doi-asserted-by":"crossref","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.081_b0125","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(97)02190-9","article-title":"Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.081_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/infdis\/jis298","article-title":"Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa","volume":"206","author":"Mlisana","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0135","doi-asserted-by":"crossref","first-page":"e1002366","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/IDR.S91260","article-title":"Pelvic inflammatory disease: improving awareness, prevention, and treatment","volume":"9","author":"Das","year":"2016","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2018.02.081_b0145","doi-asserted-by":"crossref","unstructured":"Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak DB, et al. Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study 2017. Clin Infect Dis.","DOI":"10.1093\/cid\/cix769"},{"key":"10.1016\/j.vaccine.2018.02.081_b0150","doi-asserted-by":"crossref","first-page":"e94361","DOI":"10.1371\/journal.pone.0094361","article-title":"Hospitalisations for pelvic inflammatory disease temporally related to a diagnosis of chlamydia or gonorrhoea: a retrospective cohort study","volume":"9","author":"Reekie","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.081_b0155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/01.OLQ.0000130535.96576.D3","article-title":"Chlamydia and gonorrhea co-occurrence in a high school population","volume":"31","author":"Nsuami","year":"2004","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0160","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1258\/ijsa.2008.008472","article-title":"Screening for asymptomatic chlamydia in women\u2013how often would gonorrhoea be missed?","volume":"20","author":"Rosenvinge","year":"2009","journal-title":"Int J STD & AIDS."},{"key":"10.1016\/j.vaccine.2018.02.081_b0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1071\/SH11146","article-title":"Prevalence and predictors of chlamydia co-infection among patients infected with gonorrhoea at a sexual health clinic in Sydney","volume":"9","author":"Templeton","year":"2012","journal-title":"Sexual Health"},{"key":"10.1016\/j.vaccine.2018.02.081_b0170","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/323662","article-title":"Features of Chlamydia trachomatis and Neisseria gonorrhoeae infection in male Army recruits","volume":"184","author":"Cecil","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0175","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1001\/jama.291.18.2229","article-title":"Prevalence of chlamydial and gonococcal infections among young adults in the United States","volume":"291","author":"Miller","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.02.081_b0180","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/humrep\/dex025","article-title":"Estimating infertility prevalence in low-to-middle-income countries: an application of a current duration approach to demographic and health survey data","volume":"32","author":"Polis","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.vaccine.2018.02.081_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajog.2016.08.008","article-title":"Sexually transmitted diseases and infertility","volume":"216","author":"Tsevat","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/humupd\/dmv016","article-title":"Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century","volume":"21","author":"Inhorn","year":"2015","journal-title":"Human Reprod Update"},{"key":"10.1016\/j.vaccine.2018.02.081_b0195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1258\/td.2011.100410","article-title":"Results of infertility investigations and follow-up among 312 infertile women and their partners in Kigali, Rwanda","volume":"41","author":"Dhont","year":"2011","journal-title":"Trop Doctor"},{"key":"10.1016\/j.vaccine.2018.02.081_b0200","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s12879-015-1313-1","article-title":"Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy","volume":"15","author":"Ashshi","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0205","first-page":"347","article-title":"Case-control study of ectopic pregnancies in Myanmar: infectious etiological factors","volume":"42","author":"Khin Nwe","year":"2011","journal-title":"SE Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2018.02.081_b0210","first-page":"644","article-title":"Screening for syphilis and other sexually transmitted infections in pregnant women - Guam, 2014","volume":"66","author":"Cha","year":"2017","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2018.02.081_b0215","first-page":"23","article-title":"Screening for sexually transmitted infections in pregnancy at Middlemore Hospital, 2009","volume":"125","author":"Ekeroma","year":"2012","journal-title":"New Zeal Med J"},{"key":"10.1016\/j.vaccine.2018.02.081_b0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1701-2163(15)30629-0","article-title":"A descriptive study of women presenting to an obstetric triage unit with no prenatal care","volume":"36","author":"Knight","year":"2014","journal-title":"J Obstet Gynecol Canada"},{"key":"10.1016\/j.vaccine.2018.02.081_b0225","first-page":"581","article-title":"Lower genital tract infections among pregnant women: a review","volume":"78","author":"Marai","year":"2001","journal-title":"East Afr Med J"},{"key":"10.1016\/j.vaccine.2018.02.081_b0230","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1468-3083.2011.04194.x","article-title":"Sexually transmitted infections in pregnant adolescents: prevalence and association with maternal and foetal morbidity","volume":"26","author":"Borges-Costa","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0235","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000000592","article-title":"Adverse birth outcomes and maternal Neisseria gonorrhoeae infection: a population-based cohort study in Washington state","volume":"44","author":"Heumann","year":"2017","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0240","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/sti.2004.011817","article-title":"Prevalence and risk factors of chlamydia and gonorrhea among rural Nepali women","volume":"81","author":"Christian","year":"2005","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.02.081_b0245","first-page":"471","article-title":"Epidemiology and control of gonococcal ophthalmia neonatorum","volume":"67","author":"Laga","year":"1989","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.vaccine.2018.02.081_b0250","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/0974-9233.134684","article-title":"Maternal and neonatal risk factors associated with vertical transmission of ophthalmia neonatorum in neonates receiving health care in Blantyre, Malawi","volume":"21","author":"Msukwa","year":"2014","journal-title":"Middle East African J Ophthal"},{"key":"10.1016\/j.vaccine.2018.02.081_b0255","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/1756-0500-7-784","article-title":"Ophthalmic infections in children presenting to Angkor Hospital for Children, Siem Reap, Cambodia","volume":"7","author":"Khauv","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2018.02.081_b0260","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(86)90544-1","article-title":"Epidemiology of ophthalmia neonatorum in Kenya","volume":"2","author":"Laga","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.081_b0265","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/1756-0500-6-435","article-title":"Health system support for childbirth care in Southern Tanzania: results from a health facility census","volume":"6","author":"Hanson","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2018.02.081_b0270","doi-asserted-by":"crossref","first-page":"e0170773","DOI":"10.1371\/journal.pone.0170773","article-title":"Costing of national STI program implementation for the global STI control strategy for the health sector, 2016\u20132021","volume":"12","author":"Korenromp","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.081_b0275","series-title":"The growing threat of antibiotic resistanc seminar","article-title":"What is the economic burden imposed by antimicrobial resistance in Neisseria gonorrhoeae?","author":"Tapsall","year":"2005"},{"key":"10.1016\/j.vaccine.2018.02.081_b0280","doi-asserted-by":"crossref","unstructured":"Chesson HW, Kirkcaldy RD, Gift TL, Owusu-Edusei K, Weinstock HS. An illustration of the potential health and economic benefits of combating antibiotic resistent gonorrhea. Sex Transm Dis Post Acceptance; September 22, 2017.","DOI":"10.1097\/OLQ.0000000000000725"},{"key":"10.1016\/j.vaccine.2018.02.081_b0285","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/sextrans-2016-052597","article-title":"Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?","volume":"93","author":"Ong","year":"2017","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.02.081_b0290","first-page":"190","article-title":"Epidemiology of infertility: social problems of the infertile couples","volume":"22","author":"Araoye","year":"2003","journal-title":"West Afric J Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11604\/pamj.2016.24.1.8382","article-title":"Characteristics and risk factors of preterm births in a tertiary center in Lagos, Nigeria","volume":"24","author":"Butali","year":"2016","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.vaccine.2018.02.081_b0300","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/infdis\/133.4.441","article-title":"Immunity in infection with Neisseria gonorrhoeae: duration and serological response in the chimpanzee","volume":"133","author":"Arko","year":"1976","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0305","first-page":"34","article-title":"Field trials of a gonococcal vaccine","volume":"14","author":"Greenberg","year":"1975","journal-title":"J Reprod Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0310","first-page":"29","article-title":"Gonococcal vaccine studies in Inuvik","volume":"65","author":"Greenberg","year":"1974","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2018.02.081_b0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fmicb.2011.00124","article-title":"Vaccines for gonorrhea: can we rise to the challenge?","volume":"2","author":"Zhu","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0264-410X(85)90003-9","article-title":"Pilus vaccines","volume":"3","author":"Tramont","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0325","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0264-410X(91)90147-X","article-title":"Efficacy trial of a parenteral gonococcal pilus vaccine in men","volume":"9","author":"Boslego","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0330","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development","volume":"71","author":"Rice","year":"2017","journal-title":"Ann Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0335","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1084\/jem.180.6.2181","article-title":"Genetic locus for the biosynthesis of the variable portion of Neisseria gonorrhoeae lipooligosaccharide","volume":"180","author":"Gotschlich","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0092-8674(86)90489-7","article-title":"The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion","volume":"44","author":"Haas","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.02.081_b0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0092-8674(89)90577-1","article-title":"Phase variation of gonococcal protein II: regulation of gene expression by slipped-strand mispairing of a repetitive DNA sequence","volume":"56","author":"Murphy","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.02.081_b0350","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.45.3.544-549.1984","article-title":"Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis","volume":"45","author":"Schneider","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0355","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1084\/jem.165.4.1016","article-title":"Gene conversion variations generate structurally distinct pilin polypeptides in Neisseria gonorrhoeae","volume":"165","author":"Swanson","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0360","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/IAI.67.11.5699-5708.1999","article-title":"Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice","volume":"67","author":"Jerse","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmicb.2011.00107","article-title":"Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections","volume":"2","author":"Jerse","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0370","doi-asserted-by":"crossref","first-page":"e1003559","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection","volume":"9","author":"Gulati","year":"2013","journal-title":"PLoS Path"},{"key":"10.1016\/j.vaccine.2018.02.081_b0375","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model","author":"Liu","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0380","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/315801","article-title":"Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae","volume":"182","author":"Plante","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2012.00011","article-title":"Contrasting Roles of IL-22 and IL-17 in murine genital tract infection by Neisseria gonorrhoeae","volume":"3","author":"Feinen","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0390","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/mi.2013.36","article-title":"Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells","volume":"7","author":"Liu","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0395","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/IAI.00711-09","article-title":"Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses","volume":"78","author":"Packiam","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/mi.2011.38","article-title":"Protective role of Toll-like receptor 4 in experimental gonococcal infection of female mice","volume":"5","author":"Packiam","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0405","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/infdis\/jit354","article-title":"Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12","volume":"208","author":"Liu","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0410","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","article-title":"Vaccines against gonorrhea: current status and future challenges","volume":"32","author":"Jerse","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0415","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop \u201cGonorrhea Vaccines: the Way Forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0420","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1515\/hsz-2017-0105","article-title":"Human papillomavirus first and second generation vaccines-current status and future directions","volume":"398","author":"Pouyanfard","year":"2017","journal-title":"Biol Chem"},{"key":"10.1016\/j.vaccine.2018.02.081_b0425","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.081_b0430","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1128\/IAI.73.7.3945-3953.2005","article-title":"Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice","volume":"73","author":"Price","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0435","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2012.12.132","article-title":"Recombinant truncated AniA of pathogenic Neisseria elicits a non-native immune response and functional blocking antibodies","volume":"431","author":"Shewell","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0440","unstructured":"DeRocco A SH, Sempowski G, Venetvogel M, and AE Jerse. Development of MtrE, the outer membrane channel of the MtrCDE and FarAB,MtrE active efflux pump systems, as a gonorrhea vaccine. In: Abstracts of the 19th international pathogenic Neisseria conference, Asheville, NC; 2014, Abstract O51."},{"key":"10.1016\/j.vaccine.2018.02.081_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/IAI.00898-16","article-title":"MetQ of Neisseria gonorrhoeae is a surface-expressed antigen that elicits bactericidal and functional blocking antibodies","volume":"85","author":"Semchenko","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0450","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1074\/mcp.M116.058800","article-title":"Proteomics-driven antigen discovery for development of vaccines against gonorrhea","volume":"15","author":"Zielke","year":"2016","journal-title":"Mol Cell Proteom"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.081_b0455","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1086\/513847","article-title":"Human experimentation with Neisseria gonorrhoeae: progress and goals","volume":"179","author":"Cohen","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0460","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/infdis\/169.3.532","article-title":"Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development","volume":"169","author":"Cohen","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0465","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1749-6632.1994.tb44280.x","article-title":"Inflammatory cytokine response to experimental human infection with Neisseria gonorrhoeae","volume":"730","author":"Ramsey","year":"1994","journal-title":"Annals NY Acad Sci"},{"key":"10.1016\/j.vaccine.2018.02.081_b0470","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.174.6.1601","article-title":"Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men","volume":"174","author":"Schneider","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0475","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/infdis\/173.6.1422","article-title":"Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC","volume":"173","author":"Schneider","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC","volume":"2","author":"Hobbs","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0485","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1128\/IAI.01504-14","article-title":"Phosphoethanolamine decoration of Neisseria gonorrhoeae lipid A plays a dual immunostimulatory and protective role during experimental genital tract infection","volume":"82","author":"Packiam","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0490","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fmicb.2011.00052","article-title":"New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host","volume":"2","author":"Liu","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0495","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02465-14","article-title":"\u03b1-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract","volume":"6","author":"Lewis","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2018.02.081_b0500","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/infdis\/jis277","article-title":"Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations","volume":"205","author":"Kunz","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0505","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2958.2008.06424.x","article-title":"Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness","volume":"70","author":"Warner","year":"2008","journal-title":"Mol Micro"},{"key":"10.1016\/j.vaccine.2018.02.081_b0510","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2016.06.009","article-title":"Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo","volume":"48","author":"Schmitt","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2018.02.081_b0515","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.4049\/jimmunol.1500292","article-title":"A novel factor H-Fc chimeric immunotherapeutic molecule against Neisseria gonorrhoeae","volume":"196","author":"Shaughnessy","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0520","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/381125","article-title":"Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model","volume":"189","author":"Spencer","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0525","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00007435-200107000-00010","article-title":"Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models","volume":"28","author":"Zeitlin","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0530","doi-asserted-by":"crossref","first-page":"e1005043","DOI":"10.1371\/journal.ppat.1005043","article-title":"Virulence of group A streptococci is enhanced by human complement inhibitors","volume":"11","author":"Ermert","year":"2015","journal-title":"PLoS Path"},{"key":"10.1016\/j.vaccine.2018.02.081_b0535","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.vaccine.2015.01.057","article-title":"A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice","volume":"33","author":"Pajon","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0540","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1128\/IAI.00781-07","article-title":"Transgenic mice expressing human transferrin as a model for meningococcal infection","volume":"75","author":"Zarantonelli","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0545","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/mi.2015.122","article-title":"The reproductive cycle is a pathogenic determinant during gonococcal pelvic inflammatory disease in mice","volume":"9","author":"Islam","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0550","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1172\/JCI114040","article-title":"Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection","volume":"83","author":"Plummer","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.02.081_b0555","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1172\/JCI116190","article-title":"Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection","volume":"91","author":"Plummer","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.02.081_b0560","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1172\/JCI117159","article-title":"Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis","volume":"93","author":"Plummer","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.02.081_b0565","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1128\/IAI.67.8.3937-3946.1999","article-title":"Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections","volume":"67","author":"Hedges","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.081_b0570","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-\u03b2-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0575","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1016\/j.vaccine.2008.08.020","article-title":"Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17\u03b2-estradiol-treated mice","volume":"26","author":"Song","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0580","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1056\/NEJM198506273122606","article-title":"Gonococcal infection: a model of molecular pathogenesis","volume":"312","author":"Britigan","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.02.081_b0585","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/CMR.17.4.965-981.2004","article-title":"The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women","volume":"17","author":"Edwards","year":"2004","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.vaccine.2018.02.081_b0590","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1086\/593336","article-title":"Gonococcal cervicitis: a role for biofilm in pathogenesis","volume":"198","author":"Steichen","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0595","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/126.6.601","article-title":"Adherence of Neisseria gonorrhoeae to urethral mucosal cells: an electron-microscopic study of human gonorrhea","volume":"126","author":"Ward","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0600","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1099\/00221287-113-2-383","article-title":"The intracellular survival and growth of gonococci in human phagocytes","volume":"113","author":"Veale","year":"1979","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0605","doi-asserted-by":"crossref","first-page":"390","DOI":"10.15698\/mic2016.09.525","article-title":"Chlamydia trachomatis genital infections","volume":"3","author":"O'Connell","year":"2016","journal-title":"Microbial Cell"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.081_b0610","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/652402","article-title":"Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies","volume":"201","author":"Geisler","year":"2010","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.081_b0615","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1086\/652399","article-title":"Protective immunity to chlamydial genital infection: evidence from animal studies","volume":"201","author":"Rank","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0620","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/mi.2009.139","article-title":"Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection","volume":"3","author":"Feinen","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0625","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1574-695X.2010.00759.x","article-title":"Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection","volume":"61","author":"Gagliardi","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.081_b0630","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/OLQ.0b013e31820ff9a4","article-title":"The natural history of incident gonococcal infection in adolescent women","volume":"38","author":"Stupiansky","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0635","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0b013e3182471974","article-title":"The natural history of incident gonococcal infection in adolescent women: similar observations in a female mouse model of gonococcal and chlamydial coinfection","volume":"39","author":"Vonck Stankowski","year":"2012","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.02.081_b0640","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.081_b0645","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.4161\/hv.36221","article-title":"Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model","volume":"10","author":"Regnier","year":"2014","journal-title":"Human Vacc Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T03:08:14Z","timestamp":1660964894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":129,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X18302780"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological feasibility and importance of a gonorrhea vaccine for global public health","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}